Everest Medicines (HKG: 1952), a Chinese pharmaceutical company, is set to collaborate with partners to create an innovative and integrated ecosystem focused on the diagnosis and treatment of kidney diseases. The company anticipates the imminent launch of a commercially valuable IgA kidney disease detection reagent, offering nephrologists and patients effective tools to manage the disease from onset to conclusion.
The current diagnostic gold standard for IgA nephropathy involves renal biopsy, a procedure requiring hospitalization for renal puncture surgery. This method carries risks and discomfort for patients, making it less suitable for routine monitoring of disease progression or treatment efficacy. Everest Medicines, in conjunction with its partners, is developing a novel serum detection biomarker for IgA nephropathy. This new approach utilizes an advanced chemiluminescence detection technology platform and is expected to deliver significant clinical benefits for patients with IgA nephropathy, aiding in auxiliary diagnosis, efficacy monitoring, and recurrence tracking.
Everest Medicines also announces that its first targeted therapy for IgA nephropathy will soon be commercialized in the Chinese mainland, marking a significant step forward in the treatment landscape for this disease.- Flcube.com
